Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia
暂无分享,去创建一个
G. Moulis | O. Rauzy | A. Ribes | J. Germain | V. Mansat-De Mas | Jean-Baptiste Rieu | M. Grèze | Thibaut Comont | L. Deluche | O. Walter | B. Rivière | B. Dubourdieu | Albertine Plat | Lucrecia Delarue | Isabelle LeGoff
[1] B. Bonnotte,et al. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments , 2021, HemaSphere.
[2] D. Kuter. The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists , 2021 .
[3] J. Kelton,et al. Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. , 2020, Blood advances.
[4] J. Semple,et al. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP) , 2020, Platelets.
[5] S. Vesely,et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. , 2019, Blood advances.
[6] J. Bussel,et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.
[7] Jingjing Zhu,et al. Megakaryocyte Morphological Classification Based Predictive Model for Steroid Sensitivity in Primary Immune Thrombocytopenia , 2019, Blood.
[8] J. Bussel,et al. Response to thrombopoietic agents is related to on‐treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia , 2019, American journal of hematology.
[9] J. Bussel,et al. Thrombopoietin receptor agonists: ten years later , 2019, Haematologica.
[10] S. Watson,et al. Platelets – the second growth cycle , 2018, Platelets.
[11] H. Al‐Samkari,et al. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia , 2018, American journal of hematology.
[12] J. Bussel,et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. , 2017, Blood.
[13] M. Lapeyre-Mestre,et al. Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort , 2017, American journal of hematology.
[14] J. Semple,et al. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) , 2017, Journal of clinical medicine.
[15] P. Paudyal,et al. Megakaryocytic alterations in thrombocytopenia: A bone marrow aspiration study , 2016 .
[16] M. Lapeyre-Mestre,et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. , 2014, Blood.
[17] Ashutosh Kumar,et al. Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia , 2014, Platelets.
[18] M. Lapeyre-Mestre,et al. Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies. , 2014, Therapie.
[19] Sompal Singh,et al. Morphometric evaluation of megakaryocytes in bone marrow aspirates of immune-mediated thrombocytopenic purpura , 2013, Platelets.
[20] J. Bussel,et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. , 2012, Blood.
[21] M. Pai,et al. Megakaryocytic alterations in thrombocytopenia: a bone marrow aspiration study. , 2009, Indian journal of pathology & microbiology.
[22] E. L. Luning Prak,et al. The ITP syndrome: pathogenic and clinical diversity. , 2009, Blood.
[23] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[24] J. Bussel,et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[25] J. George,et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.
[26] J. Bussel,et al. The pathogenesis of immune thrombocytopaenic purpura , 2006, British journal of haematology.
[27] E. Vellenga,et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. , 2004, Blood.